- 9 of 11 patients (82%) achieved an initial response to therapy within 2 weeks of first dose --- 5 patients have attained disease remission (an IgG4-RD Responder Index of 0) -- Every other week intravenous administration of XmAb5871 in patients with active IgG4-RD has been well tolerated -- Xencor management to host conference call today at 6:00 p.m. EST -

MONROVIA, Calif. , April 18, 2018 /PRNewswire/ -- Xencor , Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases and cancer, announced preclinical data on XmAb24306, an

MONROVIA, Calif. , Nov. 11, 2016 /PRNewswire/ -- Xencor, Inc. ( NASDAQ : XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases and cancer, today announced that data from preclinical

Abstracts available on the AACR Annual Meeting website

PASADENA, Calif. --(BUSINESS WIRE)--Nov. 3, 2023-- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today presented data from multiple preclinical-stage XmAb ® programs at the

Xencor Presents Pre-Clinical Data for Anti-CD19 Antibody at AACR Monrovia, Calif. – April 15, 2008 – Xencor, Inc., a company developing protein and antibody therapeutics, presented data from its anti-CD19 antibody program during the Annual Meeting of the American Association for Cancer Research

- 14 of 15 patients (93%) achieved a response to therapy, 12 of them within 2 weeks of first dose -- 6 patients attained disease remission (an IgG4-RD Responder Index of 0) -- Every other week intravenous administration of XmAb5871 in patients with active IgG4-RD has been well tolerated -

MONROVIA, Calif. --(BUSINESS WIRE)--Oct. 2, 2020-- Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer and autoimmune diseases, today announced initial data from its ongoing Phase 1 study of tidutamab (XmAb ®

MONROVIA, Calif. , Dec. 3, 2018 /PRNewswire/ --  Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing monoclonal antibodies for the treatment of autoimmune disease, asthma and allergic diseases, and cancer, today announced initial data from its ongoing Phase 1

-- Live webcast to review initial clinical data at 8:30 p.m. EST tonight -- MONROVIA, Calif. --(BUSINESS WIRE)--Dec. 9, 2019-- Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing monoclonal antibodies for the treatment of cancer, autoimmune disease, asthma and allergic